Late morbidity and mortality among cancer survivors with hematopoietic cell transplantation
WEDNESDAY, Nov. 30, 2016 (HealthDay News) — Hematopoietic cell transplantation (HCT) cancer survivors have increased risk of late morbidity and mortality, according to a study published online Nov. 21 in the Journal of Clinical Oncology.
Eric J. Chow, M.D., M.P.H., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared the risks of serious health outcomes for 1,792 two-year HCT survivors with 5,455 non-HCT two-year cancer survivors, frequency matched by demographic characteristics and underlying cancer diagnosis, and 16,340 individuals from the general population. Late outcomes were ascertained for all three cohorts.
The researchers found that HCT survivors experienced significantly greater rates of hospitalization (P < 0.001) and greater all-cause mortality (hazard ratio, 1.1) than non-HCT cancer survivors after a median follow-up of 7.1 years. HCT survivors had higher rates of hospitalization or death with infections and respiratory complications (both hazard ratios, 1.4). HCT survivors also had increased risks of digestive, skin, and musculoskeletal complications versus non-HCT survivors. Similar risks of circulatory complications and second cancers were seen for the two groups. Compared with the general population, both HCT and non-HCT cancer survivors had significantly greater 10-year cumulative incidences of all major organ-system outcomes.
“History of HCT was associated with late morbidity and mortality among cancer survivors,” the authors write. “In particular, clinicians who care for HCT survivors should be aware of their high rates of late respiratory and infectious complications.”
Several authors disclosed financial ties to the biopharmaceutical industry.
Full Text
Copyright © 2016 HealthDay. All rights reserved.
